Compare OneSpan Inc (OSPN) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
OneSpan Inc vs Pfizer Inc — how do they compare? OneSpan Inc trades at $15.2 (market cap $571.66M), while Pfizer Inc trades at $24.91 (market cap $142.14B). The key difference: Pfizer Inc is far larger — about 248.6× OneSpan Inc's market cap, and Pfizer Inc pays the higher dividend (6.9%). Which is the better fit depends on your goals.
| OSPN | PFE | |
|---|---|---|
Market Cap | $571.66M | $142.14B |
Sector | Technology | Health |
52-Week High | $16.32 | $28.56 |
52-Week Low | $10.15 | $23.29 |
Enterprise Value | $529.87M | $192.80B |
Dividend Yield | 3.37% | 6.9% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $15.51, up 0.26% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 28.47% net income margin and a low P/E of 8.57, indicating potential undervaluation. Recent earnings have consistently beaten expectations, and the company announced a $0.13 dividend for H1 2026. Analyst sentiment is positive with a 66.7% buy rating, though the consensus price target of $13.50 is below the current price.
The outlook for OSPN is cautiously optimistic, supported by solid fundamentals and positive earnings momentum. Key opportunities include attractive valuation and consistent profitability. Risks include negative net cash flow trends and competitive pressures in the cybersecurity sector. Investors should weigh the strong analyst buy sentiment against the below-consensus price target.
Pfizer (PFE) trades at $24.83, up 0.32% today, with a neutral technical signal and bearish moving averages. The company reported revenue of $62.58B in 2025, with a net income margin of 11.83%, and has beaten EPS estimates for the last three quarters. Recent news highlights pipeline developments in oncology and obesity, with a consensus analyst price target of $28.25.
PFE offers a stable dividend and trades below analyst targets, but faces headwinds from patent expirations and volatile cash flows. The stock presents value with a P/E of 19.04, though growth depends on successful drug launches and navigating post-COVID revenue normalization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
